Biomedical Engineering Reference
In-Depth Information
66. Bracewell C, Isaacs JD, Emery P, Ng WF. (2009) Atacicept, a
novel B cell-targeting biological therapy for the treatment of
rheumatoid arthritis. Expert Opin. Biol. Ther. 9, 909-919.
67. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R,
et al. (2001) TACI-Ig neutralizes molecules critical for B cell
development and autoimmune disease impaired B cell matu-
ration in mice lacking BLyS. Immunity 15, 289-302.
68. Vugmeyster Y, Seshasayee D, Chang W, Storn A, Howell K,
Sa S, et al. (2006) A soluble BAFF antagonist, BR3-Fc,
decreases peripheral blood B cells and lymphoid tissue
marginal zone and follicular B cells in cynomolgus monkeys.
Am. J. Pathol. 168, 476-489.
69. Lundquist L. (2007) Abatacept: a novel therapy approved for
the treatment of patients with rheumatoid arthritis. Adv. Ther.
24, 333-345.
70. Farmer DG, Shen XD, Amersi F, Anselmo D, Ma JP, Ke B,
et al. (2005) CD62 blockade with P-Selectin glycoprotein
ligand-immunoglobulin fusion protein reduces ischemia-
reperfusion injury after rat intestinal transplantation. Trans-
plantation 79, 44-51.
71. Peppel K, Crawford D, Beutler B. (1991) A tumor necrosis
factor (TNF) receptor-IgG heavy chain chimeric protein as
a bivalent antagonist of TNF activity. J. Exp. Med. 174,
1483-1489.
72. Strober BE, Menon K. (2007) Alefacept for the treatment of
psoriasis and other dermatologic diseases. Dermatol. Ther.
20, 270-276.
73. Korhonen R, Moilanen E. (2009) Abatacept, a novel
CD80/86-CD28 T cell co-stimulation modulator, in the treat-
ment of rheumatoid arthritis. Basic Clin. Pharmacol. Toxicol.
104, 276-284.
74. Davis PM, Abraham R, Xu L, Nadler SG, Suchard SJ. (2007)
Abatacept binds to the Fc receptor CD64 but does not mediate
complement-dependent cytotoxicity or antibody-dependent
cellular cytotoxicity. J. Rheumatol. 34, 2204-2210.
75. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-
Stec EM, Hartnett C, et al. (2003) Cytokine traps: multi-
component, high-affinity blockers of cytokine action. Nat.
Med. 9, 47-52.
76. Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker
MR, Jefferis R, et al. (1987) Comparison of the effector
functions of human immunoglobulins using a matched set of
chimeric antibodies. J. Exp. Med. 166, 1351-1361.
77. Jefferis R. (2007) Antibody therapeutics: isotype and glyco-
form selection. Expert Opin. Biol. Ther. 7, 1401-1413.
78. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L.
(2007) Discovery and development of the complement inhib-
itor eculizumab for the treatment of paroxysmal nocturnal
hemoglobinuria. Nat. Biotechnol. 25, 1256-1264.
79. Ashkenazi A, Chamow SM. (1995) Immunoadhesins: an
alternative to human monoclonal antibodies. Methods 8,
104.
80. International Nonproprietary Names for Pharmaceutical Sub-
stances (INN). In WHO Drug Information. 2009. vol 23.
81. Frampton JE, Lyseng-Williamson KA. (2009) Romiplostim.
Drugs 69, 307-317.
82. Nichol JL. (2006) AMG 531: an investigational thrombopoi-
esis-stimulating peptibody. Pediatr. Blood Cancer 47,
723-725.
83. Broudy VC, Lin NL, Broudy VC, Lin NL. (2004) AMG531
stimulates megakaryopoiesis in vitro by binding to Mpl.
Cytokine 25, 52-60.
84. Newland A. (2009) Romiplostim: a breakthrough treatment
for the management of immune thrombocytopenic purpura.
Eur. J. Haematol. Suppl. S.71, 20-25.
85. Stohl W, Looney RJ. (2006) B cell depletion therapy in
systemic rheumatic diseases: different strokes for different
folks? Clin. Immunol. 121, 1-12.
86. Kuchimanchi K, Narayanan A, Krzyzanski W, Wild S, Ferbas
J, Wang T, et al. Pharmacokinetics and Pharmacodynamics of
a Novel Polypeptide Fusion Protein- AMG 623 in: Cyno-
molgus Monkeys [Abstract]. AAPS aaps2007-003196.
87. Glaesner W, Vick AM, Millican R, Ellis B, Tschang SH,
Tian Y, et al. (2010) Engineering and characterization of the
long-acting glucagon-like peptide-1 analogue LY2189265,
an Fc fusion protein. Diabetes/Metab. Res. Rev. 26,
287-296.
88. Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K,
Ellis B. (2011) LY2189265, a long-acting glucagon like-
peptide-1 analog, demonstrated dose-dependent insulin
secretion in healthy subjects. Diabetes Obes. Metab. 13,
434-438.
89. Barrington P, Chien JY, Showalter HD, Schneck K, Cui S,
Tibaldi F, et al. (2011) A 5-week study of the pharmaco-
kinetics and pharmacodynamics of LY2189265, a novel,
long-acting glucagon-like peptide-1 analog, in patients
with type 2 diabetes. Diabetes Obes. Metab. 13, 426-433.
90. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone
FP, Mulcahy LS, et al. (1996) Small peptides as potent
mimetics of the protein hormone erythropoietin. Science
273, 458-464.
91. Bouman-Thio E, Franson K, Miller B, Getsy J, Cohen A,
Bai SA, et al. (2008) A phase I, single and fractionated,
ascending-dose study evaluating the safety, pharmaco-
kinetics, pharmacodynamics, and immunogenicity of an
erythropoietin mimetic antibody fusion protein (CNTO
528) in healthy male subjects. J. Clin. Pharmacol. 48,
1197-1207.
92. Bugelski PJ, Capocasale RJ, Makropoulos D, Marshall D,
Fisher PW, Lu J, et al. (2008) CNTO 530: molecular
pharmacology in human UT-7EPO cells and pharmaco-
kinetics and pharmacodynamics in mice. J. Biotechnol.
134, 171-180.
93. Picha KM, Cunningham MR, Drucker DJ, Mathur A, Ort T,
Scully M, et al. (2008) Protein engineering strategies for
sustained glucagon-like peptide-1 receptor-dependent control
of glucose homeostasis. Diabetes 57, 1926-1934.
94. Johnson DL, Farrell FX, Barbone FP, McMahon FJ, Tullai J,
Hoey K, et al. (1998) Identification of a 13 amino acid peptide
mimetic of erythropoietin and description of amino acids
critical for the mimetic activity of EMP1. Biochemistry 37,
3699-3710.
Search WWH ::
Custom Search